Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 13/20 | 0.81 |
| ▸ | MAPK13 | O15264 | 12/20 | 0.81 |
| ▸ | MAPK12 | P53778 | 12/20 | 0.81 |
| ▸ | MAPK11 | Q15759 | 12/20 | 0.81 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.46 |
| ▸ | OXTR | P30559 | 2/20 | 0.46 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6827035 | 0.90 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11AVPR2 | |
| SCHEMBL6824376 | 0.89 | MAPK14 (0.81) | MAPK14MAPK13MAPK12MAPK11MAPT | |
| SCHEMBL6825009 | 0.87 | MAPK13 (0.64) | MAPK14MAPK13MAPK12MAPK11AVPR2 | |
| SCHEMBL27690782 | 0.86 | MAPK14 (0.74) | MAPK14MAPK13MAPK12MAPK11AVPR2 | |
| SCHEMBL2201657 | 0.84 | MAPK14 (0.74) | MAPK14MAPK13MAPK12MAPK11AVPR2 | |
| SCHEMBL1906771 | 0.83 | MAPK14 (0.83) | MAPK14MAPK13MAPK12MAPK11AVPR2 | |
| SCHEMBL30242332 | 0.83 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11AVPR2 | |
| SCHEMBL1906200 | 0.83 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11AVPR2 | |
| SCHEMBL2197594 | 0.83 | MAPK13 (0.61) | MAPK14MAPK13MAPK12MAPK11AVPR2 | |
| SCHEMBL6821196 | 0.82 | MAPK14 (0.84) | MAPK14MAPK13MAPK12MAPK11EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1210325-B1 | AMINOBENZOPHENONES AS INHIBITORS OF IL-1BETA AND TNF-ALPHA | LEO PHARMA AS (DK) | 2004-10-06 | — | — | EP | claimed |
| US-6750253-B1 | INHIBITION OR DOWN REGULATION OF THE CYTOKINES IS POSSIBLY DUE TO AN INHIBITION OF MAP KINASES | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2004-06-15 | — | — | US | claimed |
| EP-1210325-A1 | AMINOBENZOPHENONES AS INHIBITORS OF IL-1BETA AND TNF-ALPHA | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 2002-06-05 | — | — | EP | claimed |
| WO-2001005751-A1 | AMINOBENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) (DK) | 2001-01-25 | — | — | WO | claimed |
| US-8293772-B2 | Triazole substituted aminobenzophenone compounds | LEO PHARMA A/S (DK) | 2012-10-23 | — | — | US | disclosed |
| EP-1658263-B9 | NOVEL AMINOBENZOPHENONE COMPOUNDS | LEO PHARMA AS (DK) | 2011-11-09 | — | — | EP | disclosed |
| US-7977387-B2 | Aminobenzophenone compounds | LEO PHARMA A/S (DK) | 2011-07-12 | — | — | US | disclosed |
| EP-1658263-B1 | NOVEL AMINOBENZOPHENONE COMPOUNDS | LEO PHARMA AS (DK) | 2010-06-02 | — | — | EP | disclosed |
| EP-1828148-B1 | TRIAZOLE SUBSTITUTED AMINOBENZOPHENONE COMPOUNDS | LEO PHARMA AS (DK) | 2010-01-20 | — | — | EP | disclosed |
| US-20060166990-A1 | Novel aminobenzophenone compounds | LEO PHARMA A/S (DK) | 2006-07-27 | — | — | US | disclosed |
| US-20060128766-A1 | Triazole substituted aminobenzophenone compounds | LEO PHARMA A/S (DK) | 2006-06-15 | — | — | US | disclosed |
| EP-1210325-B1 | AMINOBENZOPHENONES AS INHIBITORS OF IL-1BETA AND TNF-ALPHA | LEO PHARMA AS (DK) | 2004-10-06 | — | — | EP | disclosed |
| US-6750253-B1 | INHIBITION OR DOWN REGULATION OF THE CYTOKINES IS POSSIBLY DUE TO AN INHIBITION OF MAP KINASES | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2004-06-15 | — | — | US | disclosed |
| EP-1210325-A1 | AMINOBENZOPHENONES AS INHIBITORS OF IL-1BETA AND TNF-ALPHA | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 2002-06-05 | — | — | EP | disclosed |
| WO-2001005751-A1 | AMINOBENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) (DK) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128766-A1 | Triazole substituted aminobenzophenone compounds | NFKBIA, UACA, CYP1B1 | MAPK14 1089/4885MAPK13 1436/4885MAPK12 1829/4885 |
| US-20060166990-A1 | Novel aminobenzophenone compounds | NFKBIA, UACA, ALDH7A1 | MAPK14 697/4885MAPK13 1063/4885MAPK12 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.